Axovant spins out small molecule team to form CNS-focused newco

Following its pivot to gene therapy, Axovant Sciences Ltd. (NASDAQ:AXON) has spun out its small molecule team into Arvelle Therapeutics GmbH (Basel, Switzerland). The newco has raised more than $100 million and

Read the full 321 word article

User Sign In